Ash Bullement

BSc, MSc

Population Health, School of Medicine and Population Health

PhD Student

Abullement1@sheffield.ac.uk

Regent Court (ScHARR)

Full contact details

Ash Bullement
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA

Profile: I am a part-time PhD student at ScHARR, supervised by Dr Nick Latimer, Prof Matt Stevenson, and Prof Gianluca Baio (UCL). My research is focused on the use of external information to inform survival extrapolations based on clinical trials of cancer treatments. Outside of my PhD studies, I am a health economics analyst working in industry.

Qualifications

BSc Mathematics, Statistics and Operational Research, Cardiff University

MSc Health Economics and Decision Modelling, University of Sheffield

Research interests

My research interests are on the use of survival analysis methodology to estimate survival curves for use in healthcare decision making, specifically health technology assessments of cancer treatments. I am especially interested in estimating longer-term survival for treatments with novel mechanistic properties that are associated with complex hazard functions.

The working title of my PhD is ‘An exploration of methods to incorporate external information into survival modelling in oncology’.

Publications

Show: Featured publications All publications

Featured publications

This person does not have any publications available.

All publications

Journal articles

Hamerton L, Gomes K, Fougeray R, Hook ES, Gomes MV, Hauch O & Bullement A (2023) A UK cost–effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers. Future Oncology, 19(9), 643-650.
Vadgama S, Mann J, Bashir Z, Spooner C, Collins GP & Bullement A (2022) Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1. Value in Health.
Critchlow S, Xiao Y, Crabb S, Eccleston A, Christoforou K, Amin A, Bullement A, Deighton K, Chang J, Kearney M , Kapetanakis V et al (2022) POSC4 Modeling Health-Related Outcomes With Avelumab as a First-Line Maintenance Treatment Following Chemotherapy vs. Best Supportive Care (BSC) for Patients With Locally Advanced or Metastatic Urothelial Cancer in the UK. Value in Health, 25(1), S32-S33.
Bullement A (2021) Book review: Cure models: Methods, applications and implementation. Journal of the Royal Statistical Society: Series A (Statistics in Society).
Shields GE, Pennington B, Bullement A, Wright S & Elvidge J (2021) Out of date or best before? A commentary on the relevance of economic evaluations over time. PharmacoEconomics. View this article in WRRO
Bullement A, Knowles E, Langenfeld M, Diogo GR, Nazir J & Eriksson D (2021) An economic comparison of treatment strategies with anakinra in systemic juvenile idiopathic arthritis (sJIA). Open Access Rheumatology: Research and Reviews, 13, 257-266. View this article in WRRO
Bullement A, Knowles ES, DasMahapatra P, Ali T & Preblick R (2021) Cost-effectiveness analysis of rFVIIIFc versus contemporary rFVIII treatments for patients with severe hemophilia A without inhibitors in the United States. PharmacoEconomics - Open.
Hatswell AJ, Bullement A, Schlichting M & Bharmal M (2020) What is the impact of the analysis method used for health state utility values on QALYs in oncology? A simulation study comparing progression-based and time-to-death approaches. Applied Health Economics and Health Policy.
Cranmer H, Shields GE & Bullement A (2020) A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. Journal of Medical Economics, 23(10), 1176-1185.
Bullement A, Podkonjak T, Robinson MJ, Benson E, Selby R, Hatswell AJ & Shields GE (2020) Real-world evidence use in assessments of cancer drugs by NICE. International Journal of Technology Assessment in Health Care, 36(4), 388-394. View this article in WRRO
Bullement A, Willis A, Amin A, Schlichting M, Hatswell AJ & Bharmal M (2020) Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. BMC Medical Research Methodology, 20.
Bullement A, McMordie ST, Hatswell AJ, Li N & Wilson K (2020) Cost-effectiveness analysis of recombinant factor VIII Fc-fusion protein (rFVIIIFc) for the treatment of severe hemophilia A in Italy incorporating real-world dosing and joint health data. PharmacoEconomics - Open, 4, 133-142.
Gladwell D, Bullement A, Cowell W, Patterson K & Strong M (2019) "Stick or Twist?”: negotiating price and data in an era of conditional approval. Value in Health. View this article in WRRO
Bullement A, Cranmer HL & Shields GE (2019) A review of recent decision-analytic models used to evaluate the economic value of cancer treatments. Applied Health Economics and Health Policy, 17(6), 771-780. View this article in WRRO
Bullement A, Taylor M, McMordie ST, Waters E & Hatswell AJ (2019) NICE, in confidence : an assessment of redaction to obscure confidential information in single technology appraisals by the National Institute for Health and Care Excellence. PharmacoEconomics, 37(11), 1383-1390. View this article in WRRO
Cranmer H, Shields G & Bullement A (2019) PCN224 TREATMENT BENEFIT DISCONTINUATION: COMPARISON OF A PARTITIONED SURVIVAL ANALYSIS AND A SEMI-MARKOV MULTI-STATE MODEL APPROACH USING AN ONCOLOGY CASE STUDY. Value in Health, 22, S479-S479.
Bullement A, Cranmer H & Shields G (2019) PCN106 A REVIEW OF DECISION ANALYTIC MODELS TO EVALUATE THE COST-EFFECTIVENESS OF CANCER TREATMENTS: 5-YEARS OF PUBLICATIONS AND SINGLE-TECHNOLOGY APPRAISALS. Value in Health, 22, S456-S457.
Cranmer H, Shields G & Bullement A (2019) PCN103 A COMPARISON OF PARTITIONED-SURVIVAL AND STATE TRANSITION MODELLING APPROACHES - FINDINGS FROM A CASE STUDY IN ONCOLOGY. Value in Health, 22, S456-S456.
Bullement A, Nathan P, Willis A, Amin A, Lilley C, Stapelkamp C, Hatswell A, Pescott C & Bharmal M (2019) Cost effectiveness of Avelumab for metastatic Merkel cell carcinoma. PharmacoEconomics - Open, 3(3), 377-390.
Hatswell AJ, Bullement A, Schlichting M & Bharmal M (2019) PCN259 SHOULD HEALTH STATE UTILITY VALUES (HSUVS) IN CANCER IMMUNOTHERAPIES (IOS) BE ANALYZED BY TIME TO DEATH (TTD) OR PROGRESSION STATUS? RESULTS OF A SIMULATION STUDY. Value in Health, 22, S105-S105.
Bullement A, Shields G, Hatswell AJ, Schlichting M & Bharmal M (2019) ON4 REVIEW OF THE APPLICATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) DATA IN RECENT HEALTH TECHNOLOGY ASSESSMENTS (HTAS) OF CANCER IMMUNOTHERAPIES (IOS) BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE). Value in Health, 22, S44-S44.
Li N, Bullement A, McMordie S, Hatswell AJ & Wilson K (2019) RO4 COST-EFFECTIVENESS ANALYSIS OF RFVIIIFC, PEGYLATED RFVIII, AND EMICIZUMAB FOR THE PROPHYLACTIC TREATMENT OF SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN THE UNITED STATES. Value in Health, 22, S389-S389.
Bullement A, Meng Y, Cooper M, Lee D, Harding TL, O’Regan C & Aguiar-Ibanez R (2019) A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?. Journal of Medical Economics, 22(3), 205-214.
Bullement A, Latimer NR & Bell Gorrod H (2018) Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study. Value in Health. View this article in WRRO
Bharmal M, Amin A, Stapelkamp C, Pescott C, Hatswell A, Lilley C, Bullement A & Willis A (2018) Cost-effectiveness (CE) of avelumab vs standard care (SC) for the treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC). Annals of Oncology, 29, viii461-viii461.
Hatswell AJ, Bullement A, Briggs A, Paulden M & Stevenson MD (2018) Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. PharmacoEconomics. View this article in WRRO
Bullement A, Underhill S, Fougeray R & Hatswell AJ (2018) Cost-effectiveness of trifluridine/tipiracil for previously treated metastatic colorectal cancer in England and Wales. Clinical Colorectal Cancer, 17(1), e143-e151. View this article in WRRO
Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A , Fléchon A et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. The Lancet, 391(10122), 748-757.
Elvidge J, Bullement A & Hatswell AJ (2016) Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK. PharmacoEconomics, 34(11), 1145-1159.
Critchlow S, Bullement A, Crabb S, Jones R, Christoforou K, Amin A, Xiao Y, Kapetanakis V, Benedict Á, Chang J , Kearney M et al () Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology.
Gal P, Feldmajer G, Augusto M, Gani R, Hook E, Bullement A, Philips Z & Smith I () De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation. PharmacoEconomics.
Bullement A, Stevenson MD, Baio G, Shields GE & Latimer NR () A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology Assessment. Medical Decision Making, 0272989X2311686-0272989X2311686.
Cranmer HL, Shields GE & Bullement A () An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology. Applied Health Economics and Health Policy.
Gooding S, Lau I-J, Sheikh M, Roberts P, Wong J, Dickens E, Bullement A, Elvidge J, Lee D & Ramasamy K () Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs. PLOS ONE, 10(9), e0136207-e0136207.
Farmer C, Bullement A, Packman D, Long L, Robinson S, Nikram E, Hatswell AJ, Melendez-Torres GJ & Crathorne L () Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal. PharmacoEconomics.
Bullement A & Kearns B () Incorporating external trial data to improve survival extrapolations: a pilot study of the COU-AA-301 trial. Health Services and Outcomes Research Methodology.

Conference proceedings papers

Bullement A, Knowles E, van Leeuwen-Gorter A, Langenfeld M, Reynolds Diogo G, Nazir J & Eriksson D (2020) PIH4 An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (SJIA). Value in Health, Vol. 23 (pp S539-S539), 16 November 2020 - 19 November 2020.
Metry A, Sullivan W, Kearns BC & Bullement A (2019) WOULD A COHORT-LEVEL APPROACH TO COST-EFFECTIVENESS MODELLING HAVE LED TO A DIFFERENT DECISION IN AN IMPORTANT NICE APPRAISAL FOR OBESITY PATIENTS?. VALUE IN HEALTH, Vol. 22 (pp S577-S578)
Metry A, Sullivan W, Kearns BC & Bullement A (2019) PDB32 WOULD A COHORT-LEVEL APPROACH TO COST-EFFECTIVENESS MODELLING HAVE LED TO A DIFFERENT DECISION IN AN IMPORTANT NICE APPRAISAL FOR OBESITY PATIENTS?. Value in Health, Vol. 22 (pp S577-S578)
Sullivan W, Bullement A & Lee D (2018) PRM135 - DICE FOR NICE? LESSONS FROM A SINGLE TECHNOLOGY APPRAISAL. Value in Health, Vol. 21 (pp S379-S379)
Willis A, Bullement A & Sullivan W (2018) PRM133 - ESTIMATED COST SAVINGS FROM DOSE BANDING GUIDANCE: A CASE STUDY USING TREATMENTS FOR STAGE IV MELANOMA. Value in Health, Vol. 21 (pp S378-S379)
Bullement A, Amin A, Stapelkamp C, Willis A, Lilley C, Hatswell AJ, Pescott C & Bharmal M (2018) MO2 - MODELLING OVERALL SURVIVAL IN IMMUNOTHERAPY USING PARAMETRIC TECHNIQUES: AVELUMAB IN PREVIOUSLY TREATED METASTATIC MERKEL CELL CARCINOMA. Value in Health, Vol. 21 (pp S11-S11)
Gosain S, Bullement A, Kirby J, Ralph L, Lilley C & Lawrence D (2018) PSY167 - COMPARISON OF PHARMACOECONOMIC (PE) EVALUATIONS FOR DRUGS FOR RARE DISEASES (DRDS) EVALUATED BY CADTH AND NICE.. Value in Health, Vol. 21 (pp S465-S465)
Bullement A & Hatswell AJ (2018) How Errors in the Implementation of Background Mortality Leads to Bias in Models. Value in Health, Vol. 21 (pp S8-S8)
Bullement A, D'Angelo SP, Amin A, Stapelkamp C, Willis A, Lilley C, Hatswell A & Bharmal M (2018) Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab.. Journal of Clinical Oncology, Vol. 36(15_suppl) (pp e21620-e21620)
Hatswell AJ, Bullement A, Paulden M & Stevenson M (2017) Probabilistic Sensitivity Analysis In Health Economic Models; How Many Simulations Should We Run?. Value in Health, Vol. 20(9) (pp A746-A746)
Mahon S, Bullement A, Willis A, Sullivan W, Britton JA, Cox L, Tyas D & Sowdani A (2017) Cost Effectiveness of Nivolumab for Patients with Advanced, Previously Treated Renal Cell Carcinoma in Scotland. Value in Health, Vol. 20(9) (pp A440-A440) View this article in WRRO
Hatswell AJ, Cooper M, Bharmal M & Bullement A (2017) Predicting Outcomes From Multiple Uncontrolled Historical Studies of Treatment of Physician’s Choice: Progression-Free Survival And Overall Survival In Untreated Metastatic Merkel Cell Carcinoma. Value in Health, Vol. 20(9) (pp A422-A422) View this article in WRRO
Bullement A & Critchlow S (2016) An Exploration of Techniques for Addressing Uncertainty in Survival Estimates used Within Partitioned-Survival Models. Value in Health, Vol. 19(7) (pp A378-A379)
Hatswell A, Anelli M, Vigevano F, Saunders A, Bullement A & Lee D (2014) Italian Cost Minimisation Analysis: Buccolam (Midazolam Oromucosal Solution) Versus Rectal Diazepam For Prolonged Acute Epileptic Seizures. Value in Health, Vol. 17(3) (pp A61-A61)